Stock Research for BMRN


Featured Broker: Ally Invest

Get the due diligence for another stock.


BMRN Stock Chart & Research Data

The BMRN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BMRN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BMRN Due diligence Resources & Stock Charts

The BMRN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BMRN Detailed Price Forecast - CNN Money CNN View BMRN Detailed Summary - Google Finance
Yahoo View BMRN Detailed Summary - Yahoo! Finance Zacks View BMRN Stock Research & Analysis -

Stock Analysis

TradeIdeas View BMRN Trends & Analysis - Trade-Ideas Barrons View BMRN Major Holders - Barrons
NASDAQ View BMRN Call Transcripts - NASDAQ Seeking View BMRN Breaking News & Analysis - Seeking Alpha
Spotlight View BMRN Annual Report - OTC Report View BMRN OTC Short Report -
TradeKing View BMRN Fundamentals - TradeKing Charts View BMRN SEC Filings - Bar Chart
WSJ View Historical Prices for BMRN - The WSJ Morningstar View Performance/Total Return for BMRN - Morningstar
MarketWatch View the Analyst Estimates for BMRN - MarketWatch CNBC View the Earnings History for BMRN - CNBC
StockMarketWatch View the BMRN Earnings - StockMarketWatch MacroAxis View BMRN Buy or Sell Recommendations - MacroAxis
Bullish View the BMRN Bullish Patterns - American Bulls Short Pains View BMRN Short Pain Metrics -

Social Media Mentions

StockTwits View BMRN Stock Mentions - StockTwits PennyStocks View BMRN Stock Mentions - PennyStockTweets
Twitter View BMRN Stock Mentions - Twitter Invest Hub View BMRN Investment Forum News - Investor Hub
Yahoo View BMRN Stock Mentions - Yahoo! Message Board Seeking Alpha View BMRN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BMRN - Insider Cow View Insider Transactions for BMRN - Insider Cow
CNBC View BMRN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BMRN - OTC Markets
Yahoo View Insider Transactions for BMRN - Yahoo! Finance NASDAQ View Institutional Holdings for BMRN - NASDAQ

Stock Charts

FinViz View BMRN Stock Insight & Charts - StockCharts View BMRN Investment Charts -
BarChart View BMRN Stock Overview & Charts - BarChart Trading View View BMRN User Generated Charts - Trading View

Latest Financial News for BMRN

Estimates and Recommendations for Shire on September 19
Posted on Friday September 21, 2018

Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Posted on Thursday September 20, 2018

Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

BioMarin to Participate in Two Investor Conferences in October
Posted on Wednesday September 19, 2018

Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2 in New York City SAN RAFAEL, Calif. , Sept. 19, 2018 ...

What Spark Therapeutics’ Valuation Trend Indicates
Posted on Friday September 14, 2018

Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.